Newsroom

Sorted by: Latest

-

Stevanato Group to Participate in Three Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences: Tuesday, May 12, at 8:00 a.m. (PT) - Bank of America Global Healthcare Conference in Las Vegas, NV Tuesday, June 2, at 2:40 - 3:10 p.m. (CT) – William Blair Growth Stock Conference in Chi...
-

Sportradar Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Sportradar Group AG - SRAD

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Sportradar Group AG (NasdaqGS: SRAD). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit us at https://www.ksfcounsel.com/cases/nasdaqgs-srad/ to learn more.The investigation...
-

Best's Market Segment Report: AM Best Maintains Stable Outlook on Spain’s Life Insurance Segment Although Traditional Savings Business Remains Sensitive to Interest Rate Fluctuations

AMSTERDAM--(BUSINESS WIRE)--AM Best has maintained its stable outlook on Spain’s life insurance segment, noting that the positive interest rate environment over the last two years has been one of the primary drivers of the segment’s recovery. In its new Best’s Market Segment Report, “Market Segment Outlook: Spain Life Insurance”, AM Best states that higher yields have considerably improved the attractiveness of traditional savings products whose premiums increased by 26.8% in 2025. At the same...
-

Darling Ingredients Inc. to Highlight Strategic Plan for Profitable Growth at 2026 Investor Day

IRVING, Texas--(BUSINESS WIRE)--Darling Ingredients Inc. (NYSE: DAR) will host its 2026 Investor Day on Monday, May 11, 2026, at 10 a.m. Eastern Time in New York City and via a concurrent webcast. Executive leadership will provide details about the company's strategic priorities and three-year outlook. Darling Ingredients’ executives will highlight several key themes, including: Strong foundation: The company’s strategic, multi-year investments that have strengthened core assets, enhanced capab...
-

Sangoma Announces Date of Third Quarter Fiscal 2026 Financial Results and Conference Call

TORONTO--(BUSINESS WIRE)--Sangoma Technologies Corporation (TSX: STC; Nasdaq: SANG) (“Sangoma” or the “Company”), a trusted industry leader uniquely offering businesses a choice of on-premises, cloud-based, or hybrid Communications as a Service solutions, today announced that it expects to release its third quarter fiscal year 2026 results after markets close on Wednesday May 13, 2026. In addition, the Company will host a conference call on Wednesday May 13, 2026 at 5:30 PM Eastern Time to disc...
-

GreenFirst Announces Results from Annual and Special Meeting

NORTH BAY, Ontario--(BUSINESS WIRE)--GreenFirst Forest Products Inc. (TSX: GFP) (“GreenFirst” or the “Company”) is providing the voting results for the election of its Board of Directors, which took place at the Company’s Annual General Meeting which was held virtually on May 4, 2026. A total of 13,488,022 common shares were voted by proxy at the meeting representing 58.27% of the votes attached to all outstanding shares. The nominees listed in the management information circular dated March 31...
-

Roblox Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Roblox Corporation - RBLX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Roblox Corporation (NYSE: RBLX). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit us at https://www.ksfcounsel.com/cases/nyse-rblx/ to learn more. The investigation concerns whe...
-

Generational Group Advises Bradley Machine & Design LLC in its Sale to VRTX Industrial Corp.

DALLAS--(BUSINESS WIRE)--Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of Bradley Machine & Design LLC to VRTX Industrial Corp. The acquisition closed March 26, 2026. Headquartered in Chickasha, Oklahoma, Bradley Machine & Design LLC is a precision machining and fabrication shop, founded in the 1980s. The Company focuses on producing custom-machined and fabricated metal components for a wide range of i...
-

Crawford & Company Reports 2026 First Quarter Results

ATLANTA--(BUSINESS WIRE)--Crawford & Company® (NYSE: CRD-A and CRD-B), is pleased to announce its financial results for the first quarter ended March 31, 2026. Revenues before reimbursements decreased (1)% to $309.5 million in the 2026 first quarter from $312.0 million in the 2025 first quarter. First quarter net income was $4.9 million, or $0.10 per diluted share for CRD-A and CRD-B, compared to $6.7 million, or $0.13 per diluted share for CRD-A and CRD-B in the prior year quarter. GAAP Co...
-

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study designed to evaluate its novel Pressure-Enabled Drug Delivery™ (PEDD™) approach in patients w...